Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Bioverativ Therapeutics Inc. Clear all
Completed No phase listed Observational

ATHN 2: Factor Switching Study

NCT02546622
View directory record Official record
Conditions
Hemophilia
Interventions
Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Biological
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
27
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

NCT01027377
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

NCT01181128
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Factor VIII (rFVIIIFc), Advate®
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

NCT01458106
View directory record Official record
Conditions
Hemophilia A
Interventions
BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

NCT02447627
View directory record Official record
Conditions
Healthy, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

NCT02083965
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
0 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

NCT02502149
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Not listed No phase listed Observational

Natural History Study of Factor IX Treatment and Complications

NCT02502409
View directory record Official record
Conditions
Factor IX Deficiency
Interventions
Standard care with blood and urine sample collection
Other
Lead sponsor
Skane University Hospital
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

NCT01027364
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
Factor IX (rFIXFc), rFIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

NCT01440946
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc, FIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 7, 2026, 4:11 AM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 7, 2026, 4:11 AM EDT